TY - JOUR
T1 - MS-20, A chemotherapeutical adjuvant, reduces chemo-associated fatigue and appetite loss in cancer patients
AU - Chi, Kwan Hwa
AU - Chiou, Tzeon Jye
AU - Li, Chung Pin
AU - Chen, Sheng Yu
AU - Chao, Yee
N1 - Funding Information:
This study was funded by Microbio Co., Ltd, Taipei, Taiwan. DOH trial registration number: 0980303460. Kwan-Hwa Chi is one of the microbio’s consultants (Microbio Co., Ltd, Taipei, Taiwan).
Publisher Copyright:
© 2014 Taipei Veterans General Hospital.
PY - 2014/10/25
Y1 - 2014/10/25
N2 - A small pilot study of the fermented soybean extract MicrSoy-20(MS-20) demonstrated its ability to restore chemotherapy-induced immunosuppression and improve quality of life (QoL). This randomized, cross-over, comparative trial was conducted to confirm the effects of MS-20 on QoL and to understand its underlying mechanism when used in conjunction with chemotherapy. One hundred forty-three patients undergoing cancer chemotherapy were randomly assigned to 2 groups. Group 1 was administered MS-20 for 1 wk followed by 3 wk of concomitant MS-20 plus chemotherapy. Group 2 was administered chemotherapy for 3 wk. QoL was assessed by the EORTC/QLQ-C30 questionnaire and visual analogue scales (VAS). Changes in immunological parameters and antioxidant profiles were also examined. Significant increases were observed in EORTC/QLQ-C30 scores for physical (4.45, P = 0.023) and social (3.99, P = 0.023) functioning in Group 1 patients compared to Group 2 patients. VAS scores for fatigue and appetite loss significantly improved with MS-20 treatment (P < 0.001). Group 1 patients exhibited smaller decreases in peripheral blood mononuclear cells compared to Group 2 patients (P = 0.026). Other immunological parameters, antioxidant, and safety profiles were not significantly different between treatment groups. Addition of MS-20 as an adjuvant to chemotherapy can be effective in improving QoL for cancer patients.
AB - A small pilot study of the fermented soybean extract MicrSoy-20(MS-20) demonstrated its ability to restore chemotherapy-induced immunosuppression and improve quality of life (QoL). This randomized, cross-over, comparative trial was conducted to confirm the effects of MS-20 on QoL and to understand its underlying mechanism when used in conjunction with chemotherapy. One hundred forty-three patients undergoing cancer chemotherapy were randomly assigned to 2 groups. Group 1 was administered MS-20 for 1 wk followed by 3 wk of concomitant MS-20 plus chemotherapy. Group 2 was administered chemotherapy for 3 wk. QoL was assessed by the EORTC/QLQ-C30 questionnaire and visual analogue scales (VAS). Changes in immunological parameters and antioxidant profiles were also examined. Significant increases were observed in EORTC/QLQ-C30 scores for physical (4.45, P = 0.023) and social (3.99, P = 0.023) functioning in Group 1 patients compared to Group 2 patients. VAS scores for fatigue and appetite loss significantly improved with MS-20 treatment (P < 0.001). Group 1 patients exhibited smaller decreases in peripheral blood mononuclear cells compared to Group 2 patients (P = 0.026). Other immunological parameters, antioxidant, and safety profiles were not significantly different between treatment groups. Addition of MS-20 as an adjuvant to chemotherapy can be effective in improving QoL for cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84908222453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908222453&partnerID=8YFLogxK
U2 - 10.1080/01635581.2014.951731
DO - 10.1080/01635581.2014.951731
M3 - Article
C2 - 25256137
AN - SCOPUS:84908222453
SN - 0163-5581
VL - 66
SP - 1211
EP - 1219
JO - Nutrition and Cancer
JF - Nutrition and Cancer
IS - 7
ER -
